Julie Brahmer

Julie Brahmer is a pioneer in immunotherapy for thoracic malignancies who conducted early clinical trials demonstrating checkpoint inhibitor activity in SCLC. She contributed to the IMpower133 trial evaluating atezolizumab plus carboplatin-etoposide in extensive-stage SCLC, and has broadly advanced PD-1/PD-L1 inhibitor development across lung cancer histologies. Her early work on anti-PD-1 (nivolumab) safety and efficacy helped launch the field of checkpoint immunotherapy in solid tumors. She is the primary author of the ASCO/NCCN guidelines on immune-related adverse events.